ZA200602070B - Matrix metalloproteinase inhibitors - Google Patents

Matrix metalloproteinase inhibitors Download PDF

Info

Publication number
ZA200602070B
ZA200602070B ZA200602070A ZA200602070A ZA200602070B ZA 200602070 B ZA200602070 B ZA 200602070B ZA 200602070 A ZA200602070 A ZA 200602070A ZA 200602070 A ZA200602070 A ZA 200602070A ZA 200602070 B ZA200602070 B ZA 200602070B
Authority
ZA
South Africa
Prior art keywords
formula
compound
alkyl
cor
bond
Prior art date
Application number
ZA200602070A
Other languages
English (en)
Inventor
Gaines Simon
Martin Stephen Lewis
Holmes Ian Peter
Watson Stephen Paul
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA200602070B publication Critical patent/ZA200602070B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Indole Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Soft Magnetic Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Lubricants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA200602070A 2003-09-13 2006-03-10 Matrix metalloproteinase inhibitors ZA200602070B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
ZA200602070B true ZA200602070B (en) 2007-05-30

Family

ID=29227079

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200602070A ZA200602070B (en) 2003-09-13 2006-03-10 Matrix metalloproteinase inhibitors

Country Status (28)

Country Link
US (3) US7601729B2 (https=)
EP (3) EP2042488B1 (https=)
JP (3) JP2007505081A (https=)
KR (3) KR20130079628A (https=)
CN (1) CN1849306B (https=)
AT (2) ATE502922T1 (https=)
AU (1) AU2004272280C1 (https=)
BR (1) BRPI0413791A (https=)
CA (1) CA2538315C (https=)
CY (1) CY1109400T1 (https=)
DE (2) DE602004031991D1 (https=)
DK (1) DK1663970T3 (https=)
ES (2) ES2362954T3 (https=)
GB (1) GB0321538D0 (https=)
HR (1) HRP20080668T3 (https=)
IL (1) IL173305A (https=)
IS (2) IS2622B (https=)
MA (1) MA28039A1 (https=)
MX (1) MXPA06002458A (https=)
NO (1) NO20060540L (https=)
NZ (2) NZ545211A (https=)
PL (1) PL1663970T3 (https=)
PT (1) PT1663970E (https=)
RU (2) RU2370488C2 (https=)
SG (1) SG145685A1 (https=)
SI (1) SI1663970T1 (https=)
WO (1) WO2005026120A1 (https=)
ZA (1) ZA200602070B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
CA2598518C (en) * 2005-02-22 2015-04-21 Ranbaxy Laboratories Limited 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
ES2397284T3 (es) 2006-08-22 2013-03-06 Ranbaxy Laboratories Limited Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
SG187654A1 (en) 2010-07-30 2013-03-28 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
CA2812319A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
EP2926808A1 (en) 2012-11-28 2015-10-07 Administración General De La Communidad Autónoma De Euskadi Use of metalloprotease inhibitors for the treatment of polycystic liver diseases
BR112018016475A2 (en) 2016-02-12 2018-12-26 Cytokinetics, Incorporated tetrahydroisoquinoline derivatives
JP7143334B2 (ja) * 2017-06-13 2022-09-28 エシコン エルエルシー 治癒を制御させる手術用ステープラ

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1995029901A1 (en) * 1994-04-28 1995-11-09 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
CZ172498A3 (cs) * 1995-12-06 1998-12-16 Astra Pharmaceuticals Ltd. Sloučenina
WO1997040027A1 (en) * 1996-04-19 1997-10-30 Akzo Nobel N.V. Substituted benzylamines and their use for the treatment of depression
TNSN97085A1 (fr) 1996-05-15 2005-03-15 Bayer Corp Substitution oxybuterique des acides comme inhibiteurs de la matrice metalloprotease
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US6242616B1 (en) 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5789605A (en) 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US20050065353A1 (en) 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US6096904A (en) 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
MXPA03009361A (es) * 2001-04-13 2004-01-29 Boehringer Ingelheim Pharma Compuestos de urea utilies como agentes anti-inflamatorios.
WO2004012663A2 (en) * 2002-08-01 2004-02-12 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
ATE455096T1 (de) * 2002-11-19 2010-01-15 Galderma Res & Dev Biaromatische verbindungen die ppar-gamma rezeptoren aktivieren und deren anwendungen in kosmetischen oder pharmazeutischen zusammensetzungen
GB0312654D0 (en) * 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
CA2598518C (en) 2005-02-22 2015-04-21 Ranbaxy Laboratories Limited 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
ES2397284T3 (es) 2006-08-22 2013-03-06 Ranbaxy Laboratories Limited Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos

Also Published As

Publication number Publication date
IL173305A0 (en) 2006-06-11
JP2007505081A (ja) 2007-03-08
US7601729B2 (en) 2009-10-13
DK1663970T3 (da) 2009-01-12
IL173305A (en) 2011-01-31
GB0321538D0 (en) 2003-10-15
NZ545211A (en) 2009-01-31
NZ573479A (en) 2010-09-30
AU2004272280B2 (en) 2011-04-21
EP2042488A1 (en) 2009-04-01
EP1663970A1 (en) 2006-06-07
DE602004031991D1 (de) 2011-05-05
EP2042488B1 (en) 2011-03-23
KR20120007566A (ko) 2012-01-20
ES2362954T3 (es) 2011-07-15
IS2622B (is) 2010-05-15
HRP20080668T3 (hr) 2009-02-28
US8343986B2 (en) 2013-01-01
RU2006106850A (ru) 2007-10-20
MXPA06002458A (es) 2006-06-20
AU2004272280C1 (en) 2011-10-27
US20090082377A1 (en) 2009-03-26
SG145685A1 (en) 2008-09-29
CA2538315A1 (en) 2005-03-24
RU2008146479A (ru) 2010-06-20
EP1663970B1 (en) 2008-11-05
JP2012107031A (ja) 2012-06-07
PL1663970T3 (pl) 2009-04-30
ATE413384T1 (de) 2008-11-15
AU2004272280A1 (en) 2005-03-24
NO20060540L (no) 2006-04-04
US8263602B2 (en) 2012-09-11
US20100029699A1 (en) 2010-02-04
IS8268A (is) 2006-01-26
KR20060120648A (ko) 2006-11-27
PT1663970E (pt) 2009-01-09
BRPI0413791A (pt) 2006-11-07
ES2314436T3 (es) 2009-03-16
IS8843A (is) 2009-08-19
SI1663970T1 (sl) 2009-04-30
CA2538315C (en) 2014-04-08
EP2295408A1 (en) 2011-03-16
DE602004017622D1 (de) 2008-12-18
JP2011231118A (ja) 2011-11-17
CN1849306A (zh) 2006-10-18
WO2005026120A1 (en) 2005-03-24
HK1092141A1 (en) 2007-02-02
CY1109400T1 (el) 2014-07-02
US20060293353A1 (en) 2006-12-28
KR20130079628A (ko) 2013-07-10
CN1849306B (zh) 2014-01-29
MA28039A1 (fr) 2006-07-03
ATE502922T1 (de) 2011-04-15
RU2370488C2 (ru) 2009-10-20

Similar Documents

Publication Publication Date Title
US7154002B1 (en) Histone deacetylase inhibitors
ES2353020T3 (es) (piridinil)alquil-amidas o -ureas como inhibidores de la producción del tnf-alfa.
US4336381A (en) 5-Fluorouracil derivatives
EP1176956B1 (en) Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
AU2002214947B2 (en) Cyanoguanidine prodrugs
ZA200602070B (en) Matrix metalloproteinase inhibitors
KR20020084088A (ko) 히드록시피콜린산 유도체의 제조 방법
EP1189881B2 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6100273A (en) Water soluble camptothecin derivatives
US20050256160A1 (en) Beta-alanine derivatives and the use thereof
PL192864B1 (pl) Pochodna pirazyny i środek farmaceutyczny
BG62329B1 (bg) Оптично активни фунгицидни производни на 2-имидазолин-5-они/тиони
HUP0202501A2 (hu) Pirimidin-2,4,6-trion metalloproteináz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HU208811B (en) Process for producton of biaryl-compounds and pharmaceutical compositions comprising them as medical agent
EP3277662B1 (en) Hydrogen sulfide precursors and conjugates thereof
HU205917B (en) Process for producing 6-substituted pyrimidine derivatives and antiviral pharmaceutical compositions containing them as active components
US4259344A (en) Sulfur-containing benzimidazole derivatives
EP1103543A1 (en) Novel urea derivatives bearing nitrogenous aromatic heterocycles
US6765003B1 (en) 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors
US4279899A (en) Benzylpyrimidines, processes for their manufacture, and drugs containing the said compounds
CA2473763A1 (en) Compounds for modulating cell proliferation
SK5082002A3 (en) Beta disubstituted metalloprotease inhibitors
US6593323B1 (en) Benzimidazole compounds and drugs containing the same
EP0335408A2 (en) Substituted benzene derivatives, processes for their production and antitumour compositions containing them
EP0404949A1 (en) Substituted acetamide derivatives, process for their preparation and antiulcer drug containing same